Skip to main content
SpringerLink
Log in

Telbivudine in the treatment of chronic hepatitis B

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The treatment of chronic hepatitis B virus (HBV) infection has been revolutionized in the past decade by the increased availability of effective antiviral agents. Telbivudine is an L-nucleoside that is structurally related to lamivudine and has recently been approved for use in patients with chronic HBV infection. Telbivudine is highly selective for HBV DNA and inhibits viral DNA synthesis with no effect on human DNA or other viruses. This article reviews the pharmacology, pharmacokinetics, therapeutic efficacy and safety of telbivudine, and discusses its place in the current armamentarium against HBV.

Methods

Relevant publications were identified from searches of Medline and PubMed between 2000 and 2008, using the search terms “hepatitis B/HBV,” “telbivudine/LdT,” “β-L-thymidine,” “pharmacokinetics,” “safety,” “adverse events,” and “resistance.” The reference lists of retrieved articles were searched for relevant studies.

Results

Phase 3 clinical studies demonstrate that telbivudine is superior to lamivudine over a 2-year period in hepatitis B e-antigen (HBeAg)-positive and HBeAg-negative patients. Telbivudine was associated with a statistically signficantly greater reduction in HBV DNA, greater proportion of alanine aminotransferase normalization, and greater histological response than lamivudine. Furthermore, telbivudine use resulted in fewer cases of treatment failure and less virological resistance than lamivudine. However, after 2 years of therapy, telbivudine resistance was appreciable (25%) and considerably higher than that seen with other new antivirals such as tenofovir and entecavir. Overall, telbivudine was found to be safe, although grade 3 or 4 adverse events, including elevations in creatine kinase, were more commonly found in patients receiving telbivudine than lamivudine. Telbivudine is not active against lamivudine-resistant HBV.

Conclusions

Telbivudine is a new antiviral agent joining the armamentarium against HBV. It is superior to lamivudine in terms of therapeutic response and resistance profile. However, concerns about resistance with long-term use, along with inferior cost-effective analyses, have relegated telbivudine to a second-line agent in the management of chronic HBV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maynard JE. World-wide control of hepatitis B. Int J Epidemiol. 1984;13:406–407.

    Article  PubMed  CAS  Google Scholar 

  2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.

    Article  PubMed  CAS  Google Scholar 

  3. Lai C, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089–2094.

    Article  PubMed  CAS  Google Scholar 

  4. Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis e-antigenpositive chronic hepatitis B. A meta analysis. Ann Intern Med. 1993;119:312–323.

    PubMed  CAS  Google Scholar 

  5. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695.

    Article  PubMed  CAS  Google Scholar 

  6. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217.

    Article  PubMed  CAS  Google Scholar 

  7. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745.

    Article  PubMed  CAS  Google Scholar 

  8. Lok AS. Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis. 1992;10:46–52.

    Article  PubMed  CAS  Google Scholar 

  9. Hadziyannis SJ, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams & Wilkins; 1991:673–676.

    Google Scholar 

  10. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31:1037–1044.

    Article  PubMed  CAS  Google Scholar 

  11. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem specimens. N Engl J Med. 1981;305:1067–1076.

    PubMed  CAS  Google Scholar 

  12. Newbold JE, Xin H, Tencza, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69:3350–3357.

    PubMed  CAS  Google Scholar 

  13. Tuttleman JS, Porcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986;47:451–460.

    Article  PubMed  CAS  Google Scholar 

  14. Tan J, Lok AS. Update on viral hepatitis: 2006. Curr Opin Gastroenterol. 2007;23:263–267.

    Article  PubMed  CAS  Google Scholar 

  15. Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687–696.

    Article  PubMed  CAS  Google Scholar 

  16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastorenterology. 2006;131:1743–1751.

    Article  CAS  Google Scholar 

  17. Colonno RJ, Rose RE, Pokornowski, et al. Four year assessment of entecavir resistance in nucleosidenaïve and lamivudine refractory patients. Presented at: 42nd Annual Meeting of the European Association for the Study of the Liver; April 11–15, 2007; Barcelona, Spain.

  18. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.

    Article  PubMed  CAS  Google Scholar 

  19. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12(suppl. 1):119–129.

    PubMed  CAS  Google Scholar 

  20. Hernandez-Santiago B, Placidi L, Cretton-Scott E, et al. Pharmacology of beta-L-thymidine and beta-l-2′-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis b virus. Antimicrob Agents Chemother. 2002;46:1728–1733.

    Article  PubMed  CAS  Google Scholar 

  21. Seifer M, Patty A, Dukhan D, et al. Telbivudine (LdT) preferentially inhibits second (+) strand HBV DNA synthesis. J Hepatol. 2005;42(suppl. 2):151. Abstract 412.

    Google Scholar 

  22. Bryant ML, Bridges EG, Placidi L, et al. Antiviral Lnucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother. 2001;45:229–235.

    Article  PubMed  CAS  Google Scholar 

  23. Cretton-Scott E, Zhou XJ, Bridges EG, et al. Pharmacokinetics of β-L-thymidine and β-L-2′-deoxycytidine in woodchucks and monkeys. Antivir Ther. 1999;4:A124.

    Google Scholar 

  24. Hu P, Jiang J, Wang H, et al. Single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration. J Clin Pharmacol. 2006;46:999–1007.

    Article  PubMed  CAS  Google Scholar 

  25. Zhou XJ, Marbury TC, Alcorn HW, et al. Pharmacokinetics of telbivudine in subjects with various degrees of hepatic impairment. Antimicrob Agents Chemother. 2006;50:1721–1726.

    Article  PubMed  CAS  Google Scholar 

  26. Zhou XJ, Lloyd DM, Chao GC, Brown NA. Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects. J Clin Pharmacol. 2006;46:275–281.

    Article  PubMed  CAS  Google Scholar 

  27. Lai CL, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telbivudine in HBeAgpositive patients with chronic hepatitis B virus infection. Hepatology. 2004;40:719–726.

    Article  PubMed  CAS  Google Scholar 

  28. Zhou XJ, Lim SG, Lloyd DM, Chao GC, Brown NA, Lai CL. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B infection: pharmacodynamic implications. Antimicrob Agents Chemother. 2006;50:874–879.

    Article  PubMed  CAS  Google Scholar 

  29. Zhou XJ, Swan S, Smith WB, et al. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2007;51:4231–4235.

    Article  PubMed  CAS  Google Scholar 

  30. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–536.

    PubMed  CAS  Google Scholar 

  31. Lai CL, Leung N, Teo EK, et al. Phase IIb extended-treatment trial of telbivudine (LdT) vs. lamivudine vs. combination treatment in hepatitis B patients: two-year results. Gastroenterology. 2005;128(suppl. 2):A–692. Abstract 320.

    Google Scholar 

  32. Lai CL, Gane E, Liaw Y-F, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588.

    Article  PubMed  CAS  Google Scholar 

  33. Lai CL, Gane E, Hsu CW, et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine. Hepatology. 2006;44(suppl. 1):222A. Abstract 91.

    Google Scholar 

  34. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495.

    Article  PubMed  CAS  Google Scholar 

  35. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized double-blind trial. Hepatology. 2008;47:447–454.

    Article  PubMed  CAS  Google Scholar 

  36. Jia JD, Hou JL, Yin YK, et al. Two year results of a phase III comparative trial of telbivudine vs lamivudine in Chinese patients. J Hepatol. 2007;46(suppl. 1):S190. Abstract 497.

    Google Scholar 

  37. Heathcote EJ, Chan HL, Cho M, et al. A randomized trial of telbivudine (LdT) vs adefovir for HBeAg-positive chronic hepatitis B: results of the primary 24 week analysis. Gastroenterology. 2006;130(suppl. 2):A765.

    Google Scholar 

  38. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med. 2007;147:745–754.

    PubMed  Google Scholar 

  39. Shi KQ, Zhang DZ, Guo SH, et al. Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China [in Chinese]. Zhonghua Gan Zang Bing Za Zhi. 2008;16:641–645.

    PubMed  Google Scholar 

  40. Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B. Antimicrob Agents Chemother. 2008;52:2521–2528.

    Article  PubMed  CAS  Google Scholar 

  41. Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside analogue therapy. J Infect Dis. 2000;181:713–716.

    Article  PubMed  CAS  Google Scholar 

  42. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to lamivudine and adefovir. Hepatology. 2005;41:1391–1398.

    Article  PubMed  CAS  Google Scholar 

  43. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother. 2004;48:3498–3507.

    Article  PubMed  CAS  Google Scholar 

  44. Villet S, Pichoud C, Ollivet A, Villeneuvre J, Trepo C, Zoulim F. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology. 2005;42(suppl.):581A.

    Google Scholar 

  45. Gisg RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAgpositive chronic hepatitis B. Gastroenterology. 2007;133:1437–1444.

    Article  Google Scholar 

  46. Bartholomeusz A, Yuen L, Locarnini S, et al. Understanding HBV resistance to telbivudine: molecular modelling and database mining. J Hepatol. 2007;46(suppl. 1)S185. Abstract 486

    Article  Google Scholar 

  47. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro crossresistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res. 2009;81:147–155.

    Article  PubMed  CAS  Google Scholar 

  48. Standring DN, Seifer M, Patty A, et al. HBV resistance determination from the telbivudine GLOBE registration trial. J Hepatol. 2006;44(suppl. 2): S191. Abstract 514.

    Article  Google Scholar 

  49. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445–1451.

    Article  PubMed  CAS  Google Scholar 

  50. Delaney WE, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother. 2004;48:3702–3710.

    Article  PubMed  CAS  Google Scholar 

  51. Zhou XJ, Fielman BA, Lloyd DM, et al. Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil. Antimicrob Agents Chemother. 2006;50:2309–2315.

    Article  PubMed  CAS  Google Scholar 

  52. Zhou X, Pietropaolo K, Becker M, et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir. Gastroenterology. 2007;132(suppl. 2):A–766. Abstract S1782.

    Google Scholar 

  53. Zhou XJ, Fielman B, Dubuc-Patrick G, Chao G, Brown N. Absence of pharmacokinetic drug-drug interaction between telbivudine and peginterferon alpha-2a or cyclosporine in healthy subjects. J Hepatol. 2006;44(suppl. 2):S194. Abstract 522.

    Article  Google Scholar 

  54. Wong JB, Pauker SG. Cost effectiveness of telbivudine versus lamivudine for chronic hepatitis B. J Hepatol. 2007;46(suppl. 1):S199. Abstract 522.

    Article  Google Scholar 

  55. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2008;26:937–949.

    Article  PubMed  Google Scholar 

  56. National Institute for Health and Clinical Excellence. Hepatitis B — telbivudine. Telbivudine for the treatment of chronic hepatitis B. Technology appraisal TA154. August 2008. Available at: www. nice.org.uk/TA154. Accessed December 1, 208.

  57. Keeffe EB, Dieterich DT, Han SH, et al.. A treatment algorithm for the management of chronic hepatitis B infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341.

    Article  PubMed  CAS  Google Scholar 

  58. EASL Clinical practice guideline: management of chronic hepatitis B. J Hepatol. In press.

Download references

Author information

Authors and Affiliations

  1. Southampton University Hospitals Trust, Southampton General Hospital, Tremona Road, Southampton, SO23 9TN, UK

    Kathryn Nash

Authors
  1. Kathryn Nash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathryn Nash.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nash, K. Telbivudine in the treatment of chronic hepatitis B. Adv Therapy 26, 155–169 (2009). https://doi.org/10.1007/s12325-009-0004-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-009-0004-y

Keywords

Search

Navigation